Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinicalstage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thy ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $64.96, moving +1.33% from the previous trading session. This change outpaced the S&P 500's 0.9% gain on the day. On the other hand, the Dow registered a gain of 0.81%, and the technology-centric Nasdaq increased by 1.22%. Shares of the company have appreciated by 15.74% over the course of the past month, outperforming the Medical sector's loss of 4.05% and the S&P 500's gain of 3.15%. The investment community will be paying close attent ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $64.11, demonstrating a -0.9% swing from the preceding day's closing price. This change lagged the S&P 500's 0.17% loss on the day. Meanwhile, the Dow lost 0.44%, and the Nasdaq, a tech-heavy index, lost 0.04%. Coming into today, shares of the company had gained 11.34% in the past month. In that same time, the Medical sector lost 3.8%, while the S&P 500 gained 1.25%. The investment community will be closely monitoring the performance of Vi ...

An analyst waxed bullish on the company's leading pipeline program. Although Viking Therapeutics (VKTX 2.73%) is a busy company, on Monday its stock moved because of external news. A pundit reiterated his bullish take on the clinical-stage biotech, boosting sentiment on its shares and sending them nearly 3% higher in price. That was more than good enough to top the rising S&P 500 index, which closed the trading session up by 0.4%. An instant competitor Like many investors, Morgan Stanley analyst Michael Ulz ...

The company is in the spotlight for one of its programs, but it's got others that also have promise. One of the current stars of the biotech world is Viking Therapeutics (VKTX -1.11%), and for good reason. The clinical-stage company is advancing to the later stages of developing a drug that, if approved, would compete in the white-hot market for weight loss medications. While that's not the only product in the company's pipeline, it's the one that many investors have pinned their hopes on. Typically, for a ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $61.68, with a -1.03% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.13%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.39%. Shares of the company witnessed a loss of 0.53% over the previous month, beating the performance of the Medical sector with its loss of 2.05% and underperforming the S&P 500's gain of 2.43%. Investors will be eagerly watching for t ...

Viking Therapeutics NASDAQ: VKTX has captured the attention of investors, with its stock price skyrocketing over 400% in one year. This remarkable performance stems from the company's promising clinical trial results for VK2735, an investigational weight loss drug that has demonstrated promising efficacy in oral and injectable forms. Viking Therapeutics Today VKTX Viking Therapeutics $62.32 -0.81 (-1.28%) 52-Week Range $8.28 ▼ $99.41 Price Target $108.60 Add to Watchlist The company is expected to report it ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $63.13, with a +1.94% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.19%. Meanwhile, the Dow experienced a drop of 0.7%, and the technology-dominated Nasdaq saw an increase of 0.04%. Shares of the company have appreciated by 0.85% over the course of the past month, outperforming the Medical sector's loss of 1.58% and lagging the S&P 500's gain of 1.95%. Analysts and investors alike ...

Hardly for the first time, a pundit following the company waxed bullish on its future. Viking Therapeutics (VKTX 1.94%), a biotech stock that has rocketed to prominence thanks to one of its investigational drugs, gave investors more reason to like it on Wednesday. The company's share price rose by almost 2% following an analyst's bullish new research note; that increase stood in positive contrast to the 0.2% decline of the S&P 500 index. Weight loss drug in the spotlight The author of that note was Oppenhei ...

Like some other analysts, I believe that, due to the strong efficacy of Viking Therapeutics, Inc. (NASDAQ: VKTX ) weight-loss drug, VK2735, the company will probably eventually be acquired by a large pharmaceutical firm. But I think (after conducting extensive Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I a ...